Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
72 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
QCARE PHARMA CONSULT from Koekelberg, company number BE0707542348, closed financial year 2025 with a result of € 14,318 after tax. For that financial year QCARE PHARMA CONSULT recorded a gross margin of € 73,242 and equity of € 13,021. Compared with financial year 2024, the result moved from € 80,032 to € 14,318. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 12, 2026.
€ 13,021
▼ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 14,318
▼ 82% vs 2024
Profit after tax over the fiscal year.
€ 57,593
▼ 39% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 24,500 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 484
▼ 69% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 6,730
Loans from banks and other lenders, long and short.
€ 2,452
▲ 13% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 20,264
▲ 196% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 42,375 | € 88,864 | € 108,536 | € 73,242 | ▼ 33% |
| Profit after taxes | € 30,103 | € 65,850 | € 80,032 | € 14,318 | ▼ 82% |
| Equity | € 17,321 | € 18,171 | € 23,203 | € 13,021 | ▼ 44% |
| Total debts | € 58,637 | € 77,209 | € 94,065 | € 62,714 | ▼ 33% |
| Cash | € 29,560 | € 28,645 | € 93,737 | € 57,593 | ▼ 39% |
| Retained profit | € 4,921 | € 5,771 | € 10,803 | € 621 | ▼ 94% |
| Dividend | € 40,000 | € 65,000 | € 75,000 | € 24,500 | ▼ 67% |
| Bank debt | € 5,441 | € 6,758 | € 6,760 | € 6,730 | |
| Balance sheet total | € 75,958 | € 95,380 | € 117,268 | € 75,735 | ▼ 35% |
Key figures of QCARE PHARMA CONSULT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to QCARE PHARMA CONSULT?
What happened at QCARE PHARMA CONSULT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 14,318 (▼ 82% vs 2024). filed late Source: NBB ↗
- New establishment in Koekelberg. KBO
- Start of the company according to the CBE. KBO
- Moufid BELLAARI became a director. NBB
In short
From € 30,103 profit in 2022 to € 14,318 profit in 2025.
Paid € 64,977 in corporate taxes since 2022.
Best year ever: 2024, with € 80,032 profit.
Paid out € 204,500 in dividends to the owners in total.
A new publication or filing at QCARE PHARMA CONSULT? We notify you, reason included.
Follow QCARE PHARMA CONSULTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind QCARE PHARMA CONSULT is Moufid BELLAARI.
Directors
According to the 2025 annual accounts
Moufid BELLAARI
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Pantheonlaan 88 box 1
1081 Koekelberg
Pantheonlaan 88 box B01
1081 Koekelberg
Active since 1 October 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 72 companies are registered at this address.
All companies at this address →R.D. PROJECTS
€ 85,937 revenue · 2025
CLS Belgium Transport
€ 707,248 gross margin · 2025
ORK
€ 21,619 gross margin · 2025
VIPTEL
TAXIS BRUXELLES
€ 30,040 gross margin · 2024
+67 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0707.542.348
- VAT number
- BE 0707.542.348
- Registered office
- Pantheonlaan 88 bus 1, 1081 Koekelberg
- Names & denominations
- QCARE PHARMA CONSULT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 September 2018
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering